The primary Phase 1 purpose of this study is to assess overall safety and tolerability and recommended Phase 2 dose (RP2D) of SPARTA/APL-101.
The Phase 2 portion will assess the efficacy of the dose determined in Phase 1 in individuals with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors.
Who can participate in the SPARTA study?
You may be eligible to participate in the SPARTA study if you meet the following requirements:
- Are at least 18 years of age or older.
- Have been diagnosed with Non-Small Cell Lung Cancer or another advanced solid tumor with an altered c-Met pathway.
- Have not received standard cancer therapy or received standard cancer therapy that is no longer effective or is causing too many side effects.
Other requirements to participate will apply.
Complete the preliminary pre-screener to see if you qualify.
General Information
Sponsor:
Apollomics Inc.
Trial Name:
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Trial Number:
APL-101-01 (CBT-101-01)
ClinicalTrials.gov Identifier:
NCT03175224
Recruitment Status:
Pending
First Posted:
June 5, 2017
Last Update Posted:
October 30, 2020
Website:
https://www.spartacancertrial.com/
